Literature DB >> 591619

Cyproheptadine inhibition of stimulated plasma renin activity.

S Epstein, S Hamilton.   

Abstract

Plasma renin activity (PRA) was stimulated by oral frusemide (60 mg) in 4 normal male subjects. Cyproheptadine (Periactin), a serotonin antagonist, was then administered (2 mg orally four times daily) for 7 days and the PRA response to frusemide re-evaluated in the 4 subjects. A highly significant mean inhibition (P less than 0.01) of frusemide stimulated PRA was demonstrated after cyproheptadine administration. Our results show that serotonin, presumably acting via central pathways, may play a role in renin regulation and that this pathway can be inhibited by cyproheptadine.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 591619     DOI: 10.1210/jcem-45-6-1235

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

1.  Ketanserin in the treatment of diabetes-associated hypertension.

Authors:  C Beretta-Piccoli
Journal:  Drugs       Date:  1988       Impact factor: 9.546

2.  Effect of the 5-hydroxytryptamine type 2 receptor antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympatho-adrenal function in patients with essential hypertension.

Authors:  J R Zabludowski; C Zoccali; C G Isles; G D Murray; J I Robertson; G C Inglis; R Fraser; S G Ball
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

Review 3.  Serotonin and the vascular system. Role in health and disease, and implications for therapy.

Authors:  D S Houston; P M Vanhoutte
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

4.  The effect of a 5-HT antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympathoadrenal function in normal man.

Authors:  C Zoccali; J R Zabludowski; C G Isles; G D Murray; G C Inglis; J I Robertson; R Fraser; S G Ball
Journal:  Br J Clin Pharmacol       Date:  1983-09       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.